<DOC>
	<DOCNO>NCT02226900</DOCNO>
	<brief_summary>This pilot randomize study aim ass safety feasibility hybrid myocardial revascularization strategy ( coronary artery by-pass graft percutaneous intervention ) comparison conventional surgical coronary bypass grafting .</brief_summary>
	<brief_title>Myocardial Hybrid Revascularization Versus Coronary artERy Bypass GraftING Complex Triple-vessel Disease</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Triplevessel disease proximal mid LAD disease angiographic diameter stenosis &gt; 70 % visual analysis three territory , require myocardial revascularization OR triplevessel disease proximal mid LAD disease angiographic diameter stenosis 5070 % visual analysis territory invasive noninvasive evidence flowlimiting stenosis three territory , require myocardial revascularization Total SYNTAX score &gt; 22 LCx RCA territory estimate equivalently revascularized either PCI CABG , least one major nonLAD vessel treat Clinical anatomic eligibility PCI CABG agree interventional surgical consensus Interventionalist determine PCI appropriateness eligibility Surgeon determine surgical appropriateness eligibility Silent ischemia , stable angina , unstable angina recent MI If recent MI , cardiac biomarkers must return normal prior randomization Ability sign inform consent comply study procedure Prior PCI CABG time prior randomization Need concomitant cardiac surgery CABG ( e.g . valve surgery , aortic repair , etc . ) , intent patient randomize surgery , cardiac surgical procedure isolate CABG perform Patients unable tolerate , obtain comply dual antiplatelet therapy least one year Patients require additional surgery ( cardiac non cardiac ) within one year The presence clinical anatomical condition ( ) lead participate interventional cardiologist believe clinical equipoise present ( i.e . patient treat PCI , rather manage CABG medical therapy reason document ) The presence clinical anatomical condition ( ) lead participate cardiac surgeon believe clinical equipoise present ( i.e . patient treat CABG , rather manage PCI . medical therapy reason document ) Non cardiac comorbidities life expectancy le 1 year Other investigational drug device study reach primary endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Multivessel Coronary Artery Disease</keyword>
	<keyword>Hybrid Revascularization</keyword>
</DOC>